v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Mar. 31, 2026
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities      
Net loss $ (160,798) $ (176,230) $ (58,653)
Adjustments to reconcile net loss to net cash provided by operating activities:      
Depreciation and amortization   27,650 32,053
Impairment of goodwill and intangible assets 149,083 149,083 0
Non-cash gain from settlement of preexisting contractual relationship   (3,858) 0
Loss on assets held for sale   15,965 31,848
Inventory write-downs and other asset write-offs   1,883 4,326
Stock-based compensation   10,420 13,453
Amortization and accretion on marketable securities   (682) (983)
Deferred income taxes   (5,298) (4,183)
Loss (gain) on disposals of property, plant and equipment   19 (7)
Changes in operating assets and liabilities:      
Accounts receivable   8,541 6,713
Inventories   (6,700) (5,780)
Accounts payable   (4,380) 1,981
Deferred revenue   7,141 12,042
Accrued warranty and retrofit costs   (122) 343
Accrued compensation and tax withholdings   (6,245) (1,956)
Accrued restructuring costs   506 1,547
Other assets and liabilities   16,667 11,457
Net cash provided by operating activities   34,360 44,201
Cash flows from investing activities      
Purchases of property, plant and equipment   (13,595) (15,158)
Purchases of marketable securities   (328,835) (236,237)
Sales and maturities of marketable securities 123,800 266,470 184,636
Acquisition of UK Biocentre, net of cash acquired   (11,017) 0
Proceeds from other investment   0 2,130
Net investment hedge settlement   0 3,043
Deposit received for the sale of B Medical Systems business   9,000 0
Net cash used in investing activities   (77,977) (61,586)
Cash flows from financing activities      
Proceeds from issuance of common stock   1,179 1,553
Payments of finance leases   (411) (457)
Withholding tax payments on net share settlements on equity awards   (2,420) 0
Excise tax payment for settled share repurchases   0 (11,376)
Net cash used in financing activities   (1,652) (10,280)
Effects of exchange rate changes on cash, cash equivalents and restricted cash   (2,128) (4,459)
Net decrease in cash, cash equivalents and restricted cash   (47,397) (32,124)
Cash, cash equivalents and restricted cash, beginning of period   296,685 320,990
Cash, cash equivalents and restricted cash, end of period 249,288 249,288 288,866
Supplemental disclosures:      
Cash paid / (received) for income taxes, net   3,466 (4,594)
Purchases of property, plant and equipment included in accounts payable and accrued expenses   5,296 5,773
Cash and cash equivalents of continuing operations 234,033 234,033  
Cash included in current assets held for sale 8,763 8,763  
Short-term restricted cash 2,410 2,410  
Long-term restricted cash included in other assets 4,082 4,082  
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 249,288 $ 249,288 $ 288,866